Faculty

Institution

Unit

Venue

Naveen Pemmaraju

Professor Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Section Of Molecular Hematology And Therapy

Department Of Leukemia

Naveen Pemmaraju is a Professor at The University of Texas MD Anderson Cancer Center, specializing in hematology and oncology. His research focuses on acute myeloid leukemia (AML), myeloproliferative neoplasms, and blastic plasmacytoid dendritic cell neoplasm, with particular emphasis on targeted pharmacotherapies, including venetoclax, blinatumomab, and novel BCL-xL degraders. His recent work has examined triplet regimens combining hypomethylating agents with isocitrate dehydrogenase inhibitors, pharmacokinetic dose adjustments with azole antifungals, and clinico-genomic responses in secondary-type AML. He has published extensively in journals such as *Blood*, *Cancer*, and the *Journal of Clinical Oncology*, contributing to advances in epigenetic-targeted therapies and treatment paradigms for hematological malignancies.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Naveen Pemmaraju

The University of Texas MD Anderson Cancer Center

Professor Associate Professor

You can click a keyword to filter the displayed items

hematology medicine leukemia oncology hematological malignancies myeloid neoplasia pharmacology cancer research immunology pathology pharmacotherapy medicinal research bone marrow transplantation oncogenes malignant blood disorders clinical trials acute myeloid leukemia clinical research cancer care therapeutic targets cancer treatment cancer immunotherapy lymphoid neoplasia cellular therapy tumor biology clinical transplantation thrombosis phase ii study surgical oncology novel therapies cancer cells experimental medicine mixed-phenotype acute leukemia cancer discovery cancer genetics disease progression laboratory medicine chronic myeloid leukemia molecular cancer therapeutic efficacy vascular biology cell therapy blood transfusion anti-cancer agents hemostasis cancer biology cohort studies older patients myelodysplastic syndromes bone marrow failure chronic myelomonocytic leukemia clinical immunology frontline therapy myelodysplastic syndrome inotuzumab ozogamicin phase 2 phase ii trial tumor targeting treatment development myelopoiesis chronic phase therapy resistance cancer genomics clinical evidence clinical outcomes treatment options laboratory hematology prospective cohort studies malignant disease relapse prevention disease assessment retrospective cohort studies young adults acute myeloid leukaemia immunohaematology first-line treatment dermatology carcinogenesis thoracic oncology individualized medicine translational research immunotherapy surgical pathology scleroderma lung cancer jama oncology anatomical pathology radiation oncology oral pathology haematopoiesis translational medicine clinical investigation molecular diagnostics urology cancer letter sarcoma applied pharmacology molecular medicine histopathology internal medicine mesothelioma neuro-oncology

Notable Scholarly Works

Notable Federal Grants

Collaborators

Hematopoietic Effects of Tagraxofusp in Treatment‐Naive Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer (2026)

hematological malignancieshematologyhaematopoiesisoncologypathologycellular therapy

Abstract Ct246: Tagraxofusp Plus Venetoclax and Azacitidine in Patients Ineligible for Intensive Chemotherapy With Previously Untreated Cd123+ Acute Myeloid Leukemia: A Phase 2 Multicenter Trial. Cancer Research (2025)

A Case Series of Oral Decitabine–Cedazuridine With Venetoclax for Blastic Plasmacytoid Dendritic Cell Neoplasm. Leukemia & lymphoma/Leukemia and lymphoma (2025)

hematological malignanciesdermatologyleukemiahematologyanatomical pathologycancer researchlymphoid neoplasiaoncologyoral decitabine–cedazuridinecase seriespathologycellular therapy

Acute Myeloid Leukemia With Deletion 12P: An Adverse-Risk Disease. Blood (2025)

hematological malignanciesmedicineleukemiamyeloid neoplasiahematologyoncologyoncogenesacute myeloid leukemiapathology

Acute Myeloid Leukemia With T(10;17)(P15;Q21)/ I Zmynd11:: Mbtd1 /I: A Subtype With Minimal Differentiation, Cd7/Cd56 Expression, and Generally Poor Outcomes in Adults. Haematologica (2025)

immunologyhematological malignanciesmedicineleukemiamyeloid neoplasiaminimal differentiationhematologycancer researchadult t-cell leukemia-lymphomamolecular diagnosticsoncologymixed-phenotype acute leukemiaoncogenesacute myeloid leukemiapathologypoor outcomesmolecular medicine

Acute Promyelocytic Leukemia Presenting With Cranial Nerve Involvement and Clivus Mass. Acta Haematologica (2025)

Addition of Obinutuzumab After One Year of Combined Acalabrutinib and Venetoclax is Safer and Effective Than Early Obinutuzumab in a Randomized Phase II Trial for Treatment NaïVe Cll. Blood (2025)

immunologymedicinepharmacologysystemic treatmenttreatment naïve cllclinical therapeuticspharmacotherapytherapeutic targetsapplied pharmacologyclinical trialsoncologycancer treatmentcombined acalabrutinibexperimental medicine

Aml-1290: Outcomes in Patients Younger Than 50 Years Old (Yo) With Treatment-Naive Blastic Plasmacytoid Dendritic Cell Neoplasm (Bpdcn) Treated With Tagraxofusp: Subanalysis of a Phase 1/2 Trial. Clinical Lymphoma Myeloma & Leukemia (2025)

Aml-150: A Phase 1B/2 Trial of an All-Oral “Triplet” Regimen for Idh-Mutated Myeloid Malignancies: Decitabine or Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib. Clinical Lymphoma Myeloma & Leukemia (2025)

hematological malignanciesmedicineleukemiamyeloid neoplasiahematologycancer researchpharmacotherapyphase 1b/2idh-mutated myeloid malignanciesoncologyoncogenespathology

A Multicenter, Open-Label Phase 1 Study of Incb160058, a First-In-Class Jak2V617F Mutant–Selective Inhibitor, in Patients With Myelofibrosis, Polycythemia Vera, or Essential Thrombocythemia. Blood (2025)

1
2
3
4
5
112
10 / page

Naveen Pemmaraju

Professor Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Section Of Molecular Hematology And Therapy

Department Of Leukemia

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Naveen Pemmaraju

The University of Texas MD Anderson Cancer Center

Professor Associate Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Hematopoietic Effects of Tagraxofusp in Treatment‐Naive Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer (2026)

hematological malignancieshematologyhaematopoiesisoncologypathologycellular therapy

A Case Series of Oral Decitabine–Cedazuridine With Venetoclax for Blastic Plasmacytoid Dendritic Cell Neoplasm. Leukemia & lymphoma/Leukemia and lymphoma (2025)

hematological malignanciesdermatologyleukemiahematologyanatomical pathologycancer researchlymphoid neoplasiaoncologyoral decitabine–cedazuridinecase seriespathologycellular therapy

Acute Myeloid Leukemia With Deletion 12P: An Adverse-Risk Disease. Blood (2025)

hematological malignanciesmedicineleukemiamyeloid neoplasiahematologyoncologyoncogenesacute myeloid leukemiapathology

Acute Myeloid Leukemia With T(10;17)(P15;Q21)/ I Zmynd11:: Mbtd1 /I: A Subtype With Minimal Differentiation, Cd7/Cd56 Expression, and Generally Poor Outcomes in Adults. Haematologica (2025)

Acute Promyelocytic Leukemia Presenting With Cranial Nerve Involvement and Clivus Mass. Acta Haematologica (2025)

Addition of Obinutuzumab After One Year of Combined Acalabrutinib and Venetoclax is Safer and Effective Than Early Obinutuzumab in a Randomized Phase II Trial for Treatment NaïVe Cll. Blood (2025)

hematological malignanciesmedicineleukemiamyeloid neoplasiahematologycancer researchpharmacotherapyphase 1b/2idh-mutated myeloid malignanciesoncologyoncogenespathology

1
2
3
4
5
112
10 / page